SCHEMBL1285764

SCHEMBL1285764

C[C](c1ccc2cc(Br)ccc2n1)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.46
▸ NT5E P21589 1/20 0.36
▸ TLR2 O60603 1/20 0.36
▸ PTPN1 P18031 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ HSD17B14 Q9BPX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263666 0.78 BACE1 (0.50) BACE1TLR2CYP3A4CYP2C9CYP2C19
SCHEMBL262639 0.78 BACE1 (0.50) BACE1CYP3A4CYP2C9CYP2C19ABCG2
SCHEMBL1000331 0.73 MGAM (0.56) BACE1PTPN1ABCG2HDAC1HDAC2
SCHEMBL13791878 0.71 BACE1 (0.50) BACE1TLR2CYP3A4CYP2C9CYP2C19
SCHEMBL16093684 0.71 BACE1 (0.55) BACE1TLR2PTPN1ABCG2HDAC1
SCHEMBL264392 0.71 BACE1 (0.46) BACE1NT5ETLR2CYP3A4CYP2C9
SCHEMBL1003045 0.71 LMNA (0.48) BACE1ABCG2HDAC1HDAC2ALDH1A1
SCHEMBL2004085 0.71 ABCG2 (0.55) BACE1ABCG2HDAC1HDAC2ALDH1A1
SCHEMBL2723291 0.71 BACE1 (0.46) BACE1TLR2CYP3A4CYP2C9CYP2C19
SCHEMBL6954319 0.71 PTPN1 (0.53) BACE1PTPN1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 BACE1 1887/4885NT5E 2057/4885TLR2 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback